Liquid Bivalirudin Composition With pH-Controlled Shelf Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing bivalirudin formulations require reconstitution and have short shelf-lives, leading to dosing errors and instability, especially when stored at refrigerated conditions.

Innovation Solution

Development of ready-to-use liquid bivalirudin compositions with pH ranging from about 3.0 to less than 4.0 or 5.0 to 5.7, containing tonicity-adjusting and stabilizing agents, providing at least 6-month shelf life at refrigerated conditions, with reduced impurity levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If bivalirudin is formulated as a lyophilized drug product requiring reconstitution, then storage stability is improved, but ease of operation deteriorates due to multiple preparation steps and risk of dosing errors

Engineering Contradiction:
Improvestorage stabilityVSAvoidease of administration
Core Design Contradiction:
Stability of the object's compositionVSEase of operation

Solution Approach 1:

The patent changes the physical state parameter from lyophilized powder to liquid formulation, and adjusts pH parameters to specific ranges (3.0-4.0 or 5.0-5.7) to achieve both storage stability and ready-to-use convenience. This eliminates the reconstitution step while maintaining stability through controlled pH and formulation composition.

Inventive Principle:
Principle #35Parameter changes

2Ease of operation

If bivalirudin is formulated with pH 4.0-5.0 to be ready-to-use, then ease of operation is improved, but stability deteriorates due to extensive degradation after one month storage

Engineering Contradiction:
Improveready-to-use convenienceVSAvoidstorage stability
Core Design Contradiction:
Ease of operationVSStability of the object's composition

Solution Approach 1:

The patent identifies two distinct pH ranges (3.0-4.0 and 5.0-5.7) where bivalirudin remains stable for extended periods. By changing the pH parameter to these specific ranges and adjusting formulation composition including buffer systems and excipients, the patent achieves both ready-to-use convenience and long-term storage stability, resolving the degradation issue at pH 4.0-5.0.

Inventive Principle:
Principle #35Parameter changes

3Stability of the object's composition

If bivalirudin is stored at refrigerated conditions, then stability is improved, but shelf life is limited to only a few hours after reconstitution

Engineering Contradiction:
Improvestorage stabilityVSAvoidshelf life
Core Design Contradiction:
Stability of the object's compositionVSDuration of action of stationary object

Solution Approach 1:

The patent changes the formulation composition parameters including pH, buffer capacity, and excipient types to enable long-term stability at refrigerated temperatures. The liquid formulation with specific pH ranges and stabilizing components maintains potency for extended periods (months rather than hours) when stored at 2-8°C, significantly extending the usable shelf life.

Inventive Principle:
Principle #35Parameter changes

4Manufacturing precision

If multiple reconstitution and dilution steps are performed, then correct dosing is achieved, but manufacturing precision deteriorates due to incomplete dissolution and dosing errors

Engineering Contradiction:
Improvedosing accuracyVSAvoidpreparation complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent extracts and eliminates the reconstitution and dilution steps from the administration process. By providing a ready-to-use liquid formulation with predetermined concentration and volume, the patent removes the complex multi-step preparation process while ensuring dosing accuracy, thereby improving manufacturing precision and reducing preparation complexity.

Inventive Principle:
Principle #2Taking out (Extraction)

Data Source

PatentUS12472224B2Ready-to-use bivalirudin compositions
Publication Date: 2025.11.18 MAIA PHARMACEUTICALS INC

AI summary

Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.